

Author: Morin Didier Papadopoulos Vassilios Tillement Jean-Paul
Publisher: Informa Healthcare
ISSN: 1472-8222
Source: Expert Opinion on Therapeutic Targets, Vol.6, Iss.3, 2002-06, pp. : 315-334
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Ischaemia results in a decrease of blood supply to an organ. It may be sudden or progressive, partial or complete. In any case, the lack of oxygen induces a decrease in ATP generation followed by a reduction of cellular energy-dependent processes. When ischaemia is followed by a reperfusion, the efflux of oxygen in an anoxied organ promotes an excess of reactive oxygen species (ROS) generation, which impairs the restoration of ATP synthesis. Both effects induce cellular alterations that can lead to cell death in both necrotic and apoptotic forms. As ATP synthesis and ROS generation both occur in mitochondria, they are obvious targets for pharmacological interventions aiming to prevent or block deleterious effects induced by a lack of oxygen. Different approaches may be used according to the state of the pathological process under investigation. In general, prevention of the ischaemic process is more successful than the cure of the following reperfusion state. This review summarises pharmacological strategies designed to improve cellular protection before or during ischaemia–reperfusion acting via the mitochondria and highlights promising new mitochondrial targets to be considered for future therapies.
Related content


Stroke Prevention: From Available Antiplatelet Drugs to Novel Molecular Targets
Current Drug Targets, Vol. 14, Iss. 1, 2013-01 ,pp. :


Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets, Vol. 17, Iss. 12, 2016-09 ,pp. :



